Nanolive SA, a leading live cell imaging and analysis company has obtained an additional $2.2 million, closing its series C round at $22.2 million. In line with the investment, the company appointed Victoria Wang and Deborah Birx to its board of directors.
The series C investment round was led by a US-based and NASDAQ-listed life science investor – an affiliate of Innoviva, and Taiwania Capital, a leading life science venture capital company based in Taiwan. Existing investors continue to support the startup.
Following the round's closing, the startup won two experienced leaders Victoria Wang and Deborah Birx, for its board of directors. Victoria Wang is an investment principal at Taiwania Capital with extensive experience in managing biotech investments and cultivating innovative technology in the healthcare industry. Before Taiwania, she was a seasoned international business executive engaging companies to differentiate their value positioning through medical informatics and population health management.
Deborah Birx, on the other hand, is an American physician and diplomat. She served as the director of Centers for Disease Control and Prevention's Division of Global HIV/AIDS (DGHA) from 2005 to 2014 and served the United States as the White House Coronavirus Response Coordinator from 2020 to 2021.
Nanolive’s cutting-edge state-of-the-art label-free live cell digital analytical solutions provide researchers and scientists working in the biopharmaceutical industry and laboratories with all the tools required to accelerate innovation in growth industries such as drug discovery and cell therapy. Being able to screen thousands of living cells in 3D without damaging them promises to radically advance how scientists study living cells. But the quantitative analytical suite Nanolive offers is a complete game-changer. Combining sub-cellular resolution with unique AI-assisted digital assays provides researchers and scientists a unique opportunity to study complex cell-drug perturbation dynamics and cell-cell interactions (e.g., T cell and target cell interactions), quantitatively, an approach that will revolutionize the cell-based assay phase of the drug discovery workflow.
Launching the LIVE Cell Death Assay
Nanolive has today debuted its LIVE Cell Death Assay (LCDA), a push-button, automated solution for profiling cell health, death, apoptosis and necrosis, label-free. The LCDA provides first-in-class cytotoxicity analysis of dynamic label-free live cell data. Developed using state-of-the-art machine learning, the LCDA has been trained to discriminate not only living cells from dead cells, but also apoptosis from necrosis. With just a single click of a button, users can launch the analysis, which delivers 13 viability and death-related metrics.
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines